|
May 29
|
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails
|
|
May 28
|
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform
|
|
May 27
|
Update: Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued
|
|
May 27
|
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results
|
|
May 27
|
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
|
|
May 27
|
Biogen strikes RNAi deal with City; Aurion withdraws IPO
|
|
May 27
|
Why Is Prothena Stock Trading Lower On Tuesday?
|
|
May 26
|
Prothena’s Phase III trial for AL amyloidosis treatment misses endpoint
|
|
Feb 22
|
Prothena Full Year 2024 Earnings: Misses Expectations
|
|
Feb 21
|
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
|
|
Feb 21
|
Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ...
|
|
Feb 20
|
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 20
|
Prothena: Q4 Earnings Snapshot
|
|
Feb 20
|
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
|
|
Feb 4
|
Further weakness as Prothena (NASDAQ:PRTA) drops 16% this week, taking three-year losses to 61%
|
|
Dec 30
|
Prothena Announces Board of Directors Update
|